This episode currently has no reviews.
Submit ReviewNicolas Tilmans is the cofounder and CEO of Anagenex, an AI-powered drug discovery platform. They have raised $37M in funding so far from investors such as Lux Capital, Khosla Ventures, Air Street, Menlo, and Catalio. He was previously the VP of Engineering at Lumiata. He has a PhD in Biochemistry from Stanford. In this episode, we cover a range of topics including: - What are small molecule drugs and why are they challenging to develop - The founding of Anagenex - Data generation engine - DNA Encoded Libraries (DELs) - Affinity Selected Mass Spectrometry - Identifying the right targets - What's next for AI-infused drug discovery Nicolas's favorite books: - Tomorrow, and Tomorrow, and Tomorrow (Author: Gabrielle Zevin)- Letters by Abraham Lincoln (Author: Abraham Lincoln)--------Where to find Prateek Joshi: Newsletter: https://prateekjoshi.substack.com Website: https://prateekj.com LinkedIn: https://www.linkedin.com/in/prateek-joshi-91047b19 Twitter: https://twitter.com/prateekvjoshi
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review